InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,131.60
(
-0.23%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.29
(
-0.22%
)
Bitcoin
61,067.58
(
0.42%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

investor maven

Send PM Follow Ignore
Followers 5
Posts 487
Boards Moderated 0
Alias Born 10/15/2013

investor maven

Re: micanwait post# 50524

Thursday, 06/26/2014 10:01:18 AM

Thursday, June 26, 2014 10:01:18 AM

Post# of 80490
IMO the pereferred buyout scenario would be one that retains ARAID as a seperate subsidiary, similar to Imclone, Millenium and Genzyme.

That way the rapid and effective R&D can continue as well as the "high touch" apprach to patients and physicians that ARIAD excels at. The core managment would stay on, so less resistance.

Difference woudl be that there would be enough funds to expand trails on the various likely indications and allow managment to focus on that rather than raising funds.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up